Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine
Abstract
Withdrawal of dopamine agonists may precipitate or exacerbate neuroleptic malignant syndrome. This case report of neuroleptic malignant syndrome following withdrawal of neuroleptics and amantadine suggests that dopamine agonists should not be discontinued in hyperpyrexic patients at risk for this syndrome.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
